Literature DB >> 32572181

Classical-like Ehlers-Danlos syndrome: a clinical description of 20 newly identified individuals with evidence of tissue fragility.

Claire Green1, Neeti Ghali2, Glenda Sobey3, Fleur S van Dijk4, Rhoda Akilapa2, Chloe Angwin2, Duncan Baker5, Marion Bartlett2, Jessica Bowen1, Angela F Brady2, Joanna Brock5, Erin Chamberlain6, Harveer Cheema5, Vivienne McConnell7, Renarta Crookes5, Hanadi Kazkaz8, Diana Johnson1, F Michael Pope9, Anthony Vandersteen6.   

Abstract

PURPOSE: Currently, 31 patients with classical-like EDS (clEDS) due to tenascin-X deficiency have been reported in the literature. We report on the clinical and molecular characteristics of 20 additional patients with clEDS to expand knowledge and to enable improved management of this rare genetic disorder.
METHODS: Patients diagnosed with clEDS by the national EDS service in the UK (n = 21) and abroad (n = 1) were asked for consent for publication of their clinical and molecular data.
RESULTS: Of 22 patients, 20 consented. All patients had typical features of clEDS: joint hypermobility, easy bruising, and skin hyperextensibility without atrophic scars. Importantly, 3/20 patients experienced gastrointestinal complications consisting of small or large bowel ruptures and one esophageal rupture. Other notable observations included two separate occurrences of spontaneous compartment syndrome, suspicion of nonaccidental injury due to significant bruising, and significant clinical variability regarding the debilitating effect of joint dislocations.
CONCLUSIONS: We propose a predisposition to tissue fragility, particularly of the gastrointestinal tract in patients with clEDS. As such, clinical and molecular confirmation of this diagnosis is essential. It is recommended to follow up these patients closely to understand the natural history to develop better recommendations for management.

Entities:  

Keywords:  TNXB; classical-like Ehlers–Danlos syndrome; tenascin-X

Mesh:

Year:  2020        PMID: 32572181     DOI: 10.1038/s41436-020-0850-1

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  1 in total

1.  A clinical and cardiovascular survey of Ehlers-Danlos syndrome patients with complete deficiency of tenascin-X.

Authors:  A C T M Peeters; M Kucharekova; J Timmermans; F W P J van den Berkmortel; G H J Boers; I R O Nováková; D Egging; M den Heijer; J Schalkwijk
Journal:  Neth J Med       Date:  2004-05       Impact factor: 1.422

  1 in total
  5 in total

1.  Ehlers-Danlos Syndromes, Joint Hypermobility and Hypermobility Spectrum Disorders.

Authors:  Lucia Micale; Carmela Fusco; Marco Castori
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The Roles of Tenascins in Cardiovascular, Inflammatory, and Heritable Connective Tissue Diseases.

Authors:  Ken-Ichi Matsumoto; Hiroki Aoki
Journal:  Front Immunol       Date:  2020-12-01       Impact factor: 7.561

Review 3.  Ehlers-Danlos Syndrome in the Field of Psychiatry: A Review.

Authors:  Hiroki Ishiguro; Hideaki Yagasaki; Yasue Horiuchi
Journal:  Front Psychiatry       Date:  2022-01-11       Impact factor: 4.157

Review 4.  Animal Models of Ehlers-Danlos Syndromes: Phenotype, Pathogenesis, and Translational Potential.

Authors:  Robin Vroman; Anne-Marie Malfait; Rachel E Miller; Fransiska Malfait; Delfien Syx
Journal:  Front Genet       Date:  2021-10-12       Impact factor: 4.599

5.  Recurrent pneumothorax in a case of tenascin-X deficient Ehlers-Danlos syndrome: Broadening the phenotypic spectrum.

Authors:  Renee Santoreneos; Cassandra Vakulin; Melissa Ellul; Lesley Rawlings; Tristan Hardy; Nicola Poplawski
Journal:  Am J Med Genet A       Date:  2022-02-06       Impact factor: 2.578

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.